tiprankstipranks
Advertisement
Advertisement

BIIB Stock Latest News

Biogen price target lowered to $213 from $233 at RBC Capital
The FlyBiogen price target lowered to $213 from $233 at RBC Capital
2d ago
BIIB
Biogen expects Q1 results to include $34M expense on pre-tax basis
PremiumThe Fly
Biogen expects Q1 results to include $34M expense on pre-tax basis
3d ago
BIIB
Biogen price target raised to $237 from $228 at H.C. Wainwright
PremiumThe Fly
Biogen price target raised to $237 from $228 at H.C. Wainwright
7d ago
BIIB
Disney upgraded, Nike downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Disney upgraded, Nike downgraded: Wall Street’s top analyst calls
8d ago
BA
EW
Biogen price target raised to $275 from $250 at Oppenheimer
PremiumThe Fly
Biogen price target raised to $275 from $250 at Oppenheimer
8d ago
APLS
BIIB
Biogen price target raised to $245 from $230 at Canaccord
PremiumThe FlyBiogen price target raised to $245 from $230 at Canaccord
8d ago
BIIB
Biogen to Acquire Apellis, Expanding Ophthalmology Portfolio
Premium
Company Announcements
Biogen to Acquire Apellis, Expanding Ophthalmology Portfolio
9d ago
8K
BIIB
Apellis downgraded to Neutral from Buy at Citi
Premium
The Fly
Apellis downgraded to Neutral from Buy at Citi
9d ago
APLS
BIIB
Morning News Wrap-Up 3/31/26: Today’s Biggest Stock Market Stories!
PremiumMarket News
Morning News Wrap-Up 3/31/26: Today’s Biggest Stock Market Stories!
9d ago
UL
AMD
Apellis downgraded to Hold from Buy at Jefferies
PremiumThe Fly
Apellis downgraded to Hold from Buy at Jefferies
9d ago
APLS
BIIB
Chardan sees positive read-through to Annexon’s vonaprument from Apellis deal
PremiumThe Fly
Chardan sees positive read-through to Annexon’s vonaprument from Apellis deal
9d ago
ANNX
APLS
Apellis price target raised to $41 from $25 at Morgan Stanley
PremiumThe Fly
Apellis price target raised to $41 from $25 at Morgan Stanley
9d ago
APLS
BIIB
Apellis downgraded to Market Perform from Outperform at William Blair
PremiumThe FlyApellis downgraded to Market Perform from Outperform at William Blair
9d ago
APLS
BIIB
Morning Movers: Marvell jumps following Nvidia investment, AI factory pact
Premium
The Fly
Morning Movers: Marvell jumps following Nvidia investment, AI factory pact
9d ago
TE
UL
Video: Deals in food and pharmaceuticals headline busy morning of M&A
Premium
The Fly
Video: Deals in food and pharmaceuticals headline busy morning of M&A
9d ago
UL
LLY
M&A News: Apellis Pharmaceuticals Stock (APLS) Rockets over 130% after $5.6B Biogen Rare Diseases Deal
PremiumMarket News
M&A News: Apellis Pharmaceuticals Stock (APLS) Rockets over 130% after $5.6B Biogen Rare Diseases Deal
9d ago
APLS
BIIB
Biogen to acquire Apellis for $41.00 per share in cash at closing, or $5.6B
PremiumThe Fly
Biogen to acquire Apellis for $41.00 per share in cash at closing, or $5.6B
9d ago
APLS
BIIB
Biogen to acquire Apellis for $41.00 per share in cash at closing, or $5.6B
PremiumThe Fly
Biogen to acquire Apellis for $41.00 per share in cash at closing, or $5.6B
9d ago
APLS
BIIB
Biogen: Spinraza HD Approval Supports but Does Not Transform Outlook; Leqembi Execution and MS Erosion Keep Rating at Hold
PremiumRatings
Biogen: Spinraza HD Approval Supports but Does Not Transform Outlook; Leqembi Execution and MS Erosion Keep Rating at Hold
9d ago
BIIB
Biogen: Incremental Pipeline Progress and Spinraza Update Support Hold Rating Amid Ongoing Uncertainties
PremiumRatingsBiogen: Incremental Pipeline Progress and Spinraza Update Support Hold Rating Amid Ongoing Uncertainties
10d ago
BIIB
High-dose Spinraza approval, AMETHYST data drivers for Biogen, says BMO Capital
Premium
The Fly
High-dose Spinraza approval, AMETHYST data drivers for Biogen, says BMO Capital
10d ago
BIIB
Biogen announces FDA approval of high dose regimen of Spinraza
Premium
The Fly
Biogen announces FDA approval of high dose regimen of Spinraza
10d ago
BIIB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >